Marcus & Boxerman announces that it is investigating claims of potential misrepresentations by Zafgen, Inc. (“Zafgen” or the “Company”) (NASDAQ: ZFGN). The investigation will focus on whether the Company and its officers violated securities laws by issuing misleading information to investors.
To join this class action lawsuit, please contact Michael Boxerman, Esquire, of Marcus & Boxerman, at 312-216-2730, or via email at mboxerman@marcusboxerman.com.
On October 16, 2015, the Company announced that the FDA had ordered a "partial clinical hold" on the Company's Beloranib clinical trials following the death of a patient. When the truth was revealed, shares dropped, causing investors harm.
No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151126005538/en/
Contacts:
Michael Boxerman, Esq., 312-216-2730
Facsimile:
312-216-2720
mboxerman@marcusboxerman.com
